Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burnett, A. L. B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Burnett, A. L. B.
Journal of Andrology, Vol. 24, No. 90060, 2003
Copyright © American Society of Andrology

Prologue

ARTHUR L. "BUD" BURNETT

From The Johns Hopkins Hospital, Baltimore, Maryland.

Correspondence to: Arthur L. "Bud" Burnett, MD, Course Director, The Johns Hopkins Hospital, 600 N Wolfe St, Marburg 407, Baltimore, MD 21287-2411.


This journal supplement was conceived to serve as an enduring presentation associated with the American Society of Andrology 28th Annual Meeting's Postgraduate Course entitled "Erectile Dysfunction and Androgens." A primary theme of the course centered on the relationship between erection physiology and androgens, with consideration of the most current concepts relating to these subject areas. Indeed, great debate has persisted regarding whether androgens necessarily influence the erection response. In an attempt to move toward the answer, the course was assembled with the assignment for presenters to examine the facts supporting this relationship, acknowledge deficiencies in knowledge within these areas, and suggest critical aspects for further scientific investigation.

An additional objective of the course generated from the recognition that the field of sexual medicine has been dramatically transformed by scientific accomplishments in erection physiology over the past decade, providing the critical foundation for the emergence of oral pharmacotherapy for erectile dysfunction. The course provided an opportunity to review the science of phosphodiesterase-5 biology in penile erection and update the application of currently developed phosphodiesterase-5 inhibitor therapy in the treatment of erectile dysfunction.

By design, the course contained a series of basic science presentations intended to represent major regulatory levels of erection physiology. These presentations provided background for the clinical content to follow oriented toward behavioral modifications and pharmacologic interventions in the management of erectile dysfunction. As would be expected, particular roles for androgen replacement and phosphodiesterase-5 inhibitor therapy in men with erectile dysfunction were highlighted.

Words of appreciation are accorded all presenters, experts in their respective subject areas, whose solid contributions brought this supplement to fruition. Conceivably, the supplement will acceptably serve as an enduring resource for those attending the course to review and for those unable to attend the course to consult. Special thanks is due the corporate sponsors for the course and the supplement, Bayer, Lilly ICOS, and Pfizer. Without their assistance, this achievement would not have been possible.





This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burnett, A. L. B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Burnett, A. L. B.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS